---
title: "Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291516383.md"
description: "Today, in Zug, Switzerland, on July 2, 2026, Oculis Holding AG, a global biopharmaceutical company concentrating on neuro-ophthalmic and ophthalmic disease solutions where medical needs remain unmet, disclosed their involvement at the Piper Sandler Virtual Ophthalmology Conference. The company's management team will partake in a fireside discussion at the event. Oculis is listed under the ticker symbols Nasdaq: OCS and XICE: OCS."
datetime: "2026-07-02T08:01:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291516383.md)
  - [en](https://longbridge.com/en/news/291516383.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291516383.md)
generator: "portal-rs"
---

# Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

Today, in Zug, Switzerland, on July 2, 2026, Oculis Holding AG, a global biopharmaceutical company concentrating on neuro-ophthalmic and ophthalmic disease solutions where medical needs remain unmet, disclosed their involvement at the Piper Sandler Virtual Ophthalmology Conference. The company's management team will partake in a fireside discussion at the event. Oculis is listed under the ticker symbols Nasdaq: OCS and XICE: OCS.

### Related Stocks

- [OCS.US](https://longbridge.com/en/quote/OCS.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [OCSAW.US](https://longbridge.com/en/quote/OCSAW.US.md)

## Related News & Research

- [Oculis directors vest and settle RSUs, filings show](https://longbridge.com/en/news/295969673.md)
- [Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results](https://longbridge.com/en/news/295310504.md)
- [Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference | OCS Stock News](https://longbridge.com/en/news/291514512.md)
- [Prepayments (CK93) - Nykredit Realkredit A/S](https://longbridge.com/en/news/296067760.md)
- [IMM: First-in-class immunotherapies efti and IMP761 advance in oncology and autoimmunity](https://longbridge.com/en/news/296543630.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**